Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3101-3109

  Gridley, Daila S ^a,d   Makinde, Adeola Y ^a   Luo, Xian ^a   Rizvi, Asma ^a   Crapo, James D ^b   Dewhirst, Mark W ^c   Moeller, Benjamin J ^c   Pearlstein, Robert D ^c   Slater, James M ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Antioxidant; Cytokines; HIF 1 ; Immune system; Ionizing radiation; RM 9 prostate cancer

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 4; MAGNESIUM TETRAKIS(1,3 DIETHYLIMIDAZOLIUM 2 YL)PORPHYRIN; METALLOPORPHYRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MASS; BONE MARROW CELL; CELL POPULATION; CELL SUBPOPULATION; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; RADIATION; SPLEEN SIZE; TUMOR VOLUME;

ANIMALS; ANTIOXIDANTS; B-LYMPHOCYTES; BODY WEIGHT; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; MALE; METALLOPORPHYRINS; MICE; MICE, INBRED C57BL; ORGAN SIZE; PROSTATIC NEOPLASMS; RADIATION-PROTECTIVE AGENTS; SPLEEN; T-LYMPHOCYTES;

EID: 35348987605     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Chism DB, Horwitz EM, Hanlon AL, Pinover WH, Mitra RK and Hanks GE: Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Oncol Biol Phys 55: 71-77, 2003.
2. Hanks GE, Martz KL and Diamond JJ: The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 15: 1299-1303, 1988.
3. Hanks GE, Coia LR and Curry J: Patterns of care studies: past, present, and future. Semin. Radiat Oncol 7: 97-100, 1997.
4. Storey MR, Pollack A, Zagars G, Smith L, Antolak J and Rosen I: Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial, Int J Radiat Oncol Biol Phys 48: 635-642, 2000.
5. Crapo JD: Oxidative stress as an initiator of cytokine release and cell damage. Eur Respir J Suppl 44: 4s-6s, 2003.
6. Gridley DS, Green LM, Nelson GA, Pecaut MJ and Slater JM: Cancer, radiotherapy and SOD mimetics. In: Therapeutic Applications of Superoxide Dismutase and Its Mimetics. D Salvemini and S Cuzzocrea (eds.). Georgetown: Landes and New York: Springer, 2006.
7. Rubin P, Johnston CJ, Williams JP, McDonald S and Finkelstein JN: A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33: 99-109, 1994.
8. Vujaskovic Z, Anscher MS, Feng QF, Rabbani ZN, Amin K, Samulski TA, Dewhirst MW, and Haroon ZA: Radiation-induced hypoxia may perpetuate late normal tissue injury. Int. J. Radiat Oncol Biol Phys 50: 851-855, 2001.
9. Corominas M, Bas J, Romeu A, Valls A, Massip E, Gonzalez L, Mestre M and Buendia E: Hypersensitivity reaction after orgotein (superoxide dismutase) administration. Allergol Immunopathol (Madr) 18: 297-299, 1990.
10. Jadot G, Vaille A, Maldonado J and Vanelle P: Clinical pharmacokinetics and delivery of bovine superoxide dismutase. Clin Pharmacokinet 28: 17-25, 1995.
11. Kumar KS, Vaishnav YN and Weiss JF: Radioprotection by antioxidant enzymes and enzyme mimetics. Pharmac Ther 39: 301-330, 1988.
12. Chang LY and Crapo JD: Inhibition of airway inflammation and hyperreactivity by anantioxidant mimetic. Free Radic Biol Med 33: 379-386, 2002.
13. Day BJ: Catalytic antioxidants: a radical approach to new therapeutics. Drug Discov Today 9: 557-566, 2004.
14. Bowler RP, Sheng H, Enghild JJ, Pearlstein RD, Warner DS and Crapo JD: A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. Free Radic Biol Med 33: 1141-1152, 2002.
15. Sheng H, Enghild JJ, Bowler R Patel M, Batinic-Haberle I, Calvi C, Day BJ, Pearlstein RD, Crapo JD and Warner DS: Effects of metalloporphyrin catalytic antioxidants in experimental brain ischemia. Free Radic Biol Med 33: 947-961, 2002.
16. Smith KR, Uyeminami DL, Kodavanti UP, Crapo JD, Chang LY and Pinkerton KE: Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic Biol Med 33: 1106-1114, 2002.
17. Lee JH, Lee YM and Park JW: Regulation of ionizing radiation-induced apoptosis by a manganese porphyrin complex. Biochem Biophys Res Commun 334: 298-305, 2005.
18. Vujaskovic Z, Batinic-Haberle I, Rabbani ZN, Feng QF, Kang SK, Spasojevic I, Samulski TV, Fridovich I, Dewhirst MW and Anscher MS: A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic Biol Med 33: 857-863, 2002.
19. Rabbani ZN, Anscher MS, Golson ML, Chen L, Archer E, Folz RJ, Samulski TV, Dewhirst MW and Vujaskovic Z: Overexpression of extracellular superoxide dismutase reduces severity of radiation-induced lung toxicity through downregulation of the TGF-beta signal transduction pathway. Int J Radiat Oncol Biol Phys 57: S158-S159, 2003.
20. Lee JH and Park JW: A manganese porphyrin complex is a novel radiation protector. Free Radic Biol Med 37: 272-283, 2004.
21. Moeller BJ, Cao Y, Li CY and Dewhirst MW: Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 429-441, 2004.
22. Moeller BJ, Batinic-Haberle I, Spasojevic I, Rabbini ZN, Anscher MS, Vujaskovic Z and Dewhirst MW: A manganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness. Int J Radiat Oncol Biol Phys 63: 545-552, 2005.
23. Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY and Dewhirst MW: Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8: 99-110, 2005.
24. Thompson TC, Timme TL, Park SH Yang G and Ren C: Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease. The Prostate 43: 248-254, 2000.
25. Crapo JD, Day BJ and Fridovich I: Development of manganic porphyrin mimetics of superoxide dismutase activity. In: Therapeutic Applications of Superoxide Dismutase and Its Mimetics. D Salvemini and S Cuzzocrea (eds.). Landes: Georgetown and Springer, 2006.
26. Miller GM, Andres ML and Gridley DS: NK cell depletion results in accelerated tumor growth and attenuates the antitumor effect of total body irradiation. Int J Oncol 23: 1585-1592, 2003.
27. Luo X, Kim DW, Crapo JD, Pearlstein R, Slater JM and Gridley DS: Differential modification of tumor and normal cell response to radiation by a metalloporphyrin antioxidant. 52nd Ann Meeting of the Radiation Research Society (RRS), Oct. 16-19, 2005. Denver, CO. www.radres.org
28. Guo H, Epperly MW, Bernarding M, Nie S, Gretton J, Jefferson M and Greenberger JS: Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) intratracheal gene therapy reduction of irradiation-induced inflammatory cytokines does not protect orthotopic Lewis lung carcinomas. In Vivo 17: 13-21, 2003.
29. Church SL, Grant JW, Ridnour LA, Oberley LW, Swanson PE, Meltzer PS and Trent JM: Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc Natl Acad Sci USA 90: 3113-3117, 1993.
30. Li JJ, Oberley LW, St Clair DK, Ridnour LA and Oberley TD: Phenotypic changes induced in human breast cancer cells by overexpression of manganese-containing superoxide dismutase. Oncogene 10: 1989-2000, 1995.
31. Zhong W, Oberley LW, Oberley TD and St Clair DK: Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene 14: 481-490, 1997.
32. Vujaskovic Z, Moeller B, Batinic-Haberle I, Spasojevic I, Rabbani ZN, Dewhirst MW and Anscher MS: Sequencing effects of a superoxide dismutase mimetic on tumor radioresponsiveness. Int J Radiat Oncol Biol Phys 57: S159, 2003.
33. Moeller BJ, Cao Y, Vujaskovic Z and Dewhirst MW: Reactive oxygen species and hypoxia inducible factor-1alpha serve as important vascular stabilizing elements in tumors following radiotherapy. Int J Radiat Oncol Biol Phys 57: S320-S321, 2003.
34. Rasey JS, Koh WJ, Evans ML Peterson LM, Lewellen TK, Graham MM and Krohn KA: Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36: 417-428, 1996.
35. Moeller BJ and Dewhirst MW: Raising the bar: how HIF-1 helps determine tumor radiosensitivity. Cell Cycle 3: 1107-1110, 2004.
36. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
37. McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F, Dougherty GJ, Iwamoto KS, Pervan M and Liao YP: A sense of danger from radiation. Radiat Res 162: 1-19, 2004.
38. Arlen PM and Gulley JL: Therapeutic vaccines for prostate cancer: a review of clinical data. Curr Opin Investig Drugs 6: 592-596, 2005.
39. Jakobisiak M, Lasek W and Golab J: Natural mechanisms protecting against cancer. Immunol Lett 90: 103-122, 2003.
40. Moldovan L and Moldovan NI: Role of monocytes and macrophages in angiogenesis. EXS (Basel) 94: 127-146, 2005.
41. Monaco C, Andreakos E, Kiriakidis S, Feldmann M and Paleolog E: T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy 3: 35-42, 2004.
42. Scapini P, Calzetti F and Casseatella MA: On the detection of neutrophil-derived vascular endothelial growth factor (VEGF). J Immunol Methods 232: 121-129, 1999.
43. Tse HM, Milton MJ and Piganelli JD: Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: Implications for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic Biol Med 36: 233-247, 2004.
44. Volpert O, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI and Bouck NP: Inhibition of angiogenesis by interleukin 4. J Exp Med 188: 1039-1046, 1998.
45. Borden EC: Review: Milstein Award lecture: interferons and cancer: where from here? J Interferon Cytokine Res 25: 511-527, 2005.
46. Naldini A and Carraro F: Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy 4: 3-8, 2005.
47. Peter RU, Gottlober P, Nadeshina N, Krahn G, Braun-Falco O and Plewig G: Interferon gamma in survivors of the Chernobyl power plant accident: new therapeutic option for radiation-induced fibrosis. Int J Radiat Oncol Biol Phys 45: 147-152, 1999.
48. Cemerski S, van Meerwijk JP and Romagnoli P: Oxidative-stress-induced T lymphocyte hyporesponsiveness is caused by structural modification rather than proteasomal degradation of crucial TCR signaling molecules. Eur J Immunol 33: 2178-2185, 2003.